Journal of nanobiotechnology · 2026
A novel mRNA-based multi-cytokine strategy to reprogram the peritoneal tumor microenvironment in ovarian cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Yu-Sun, Lee Jisun, Lee Yeeun, Yoon Hyunho, Bae Seo-Hyeon, Yoon Subin, Lee Seonghyun, Roh Gahyun, Cho Youngran, Cho Seongje, Ha Dahyeon, Oh Ayoung, Lee Soo-Yeon, Choi Eun-Jin, Choi Huijeong, Jo Sohee, Kim Jungmin, Lee Sowon, Park Hyo-Jung, Jeon Seoyoung, Park Sang-In, Yang Wookyeom, Kim Jae Hoon, Choi Tae Gyu, Nam Jae-Hwan
Аннотация
BACKGROUND: Peritoneal dissemination is a hallmark feature of advanced ovarian cancer and significantly contributes to its poor prognosis. An intraperitoneal mRNA-based immunotherapy delivering a combination of single-chain interleukins (IL), including IL-12, IL-15, pro-IL-18, and Caspase-1, encapsulated in lipid nanoparticles, is administered to reprogram the immunosuppressive tumor microenvironment (TME) in a syngeneic ID8-Fluc ovarian cancer mouse model.
RESULTS: This mRNA cocktail effectively suppresses tumor growth, reduces malignant ascites, and inhibits metastasis. Immune profiling reveals enhanced infiltration of effector CD8⁺ and CD4⁺ T cells, reduced regulatory T cells, and decreased expression of exhaustion markers such as TIM-3 and PD-1. Macrophage populations are shifted from immunosuppressive M2 to proinflammatory M1 phenotypes, with increased monocyte infiltration, indicating robust myeloid reprogramming. Although mRNA-expressed IL-12 monotherapy exhibits potent antitumor effects, the combination of IL-15, IL-18, and Caspase-1 elicits superior therapeutic efficacy. Although high-dose treatment induces hepatotoxicity and weight loss, a reduced-dose regimen maintains efficacy with improved safety.
CONCLUSIONS: This study demonstrates the therapeutic potential of mRNA-based cytokine combinations to transform the ovarian cancer immune landscape. The modularity, localized delivery, and tunable expression of this platform provide a compelling framework for future mRNA immunotherapies targeting solid tumors with immunosuppressive TMEs.
RESULTS: This mRNA cocktail effectively suppresses tumor growth, reduces malignant ascites, and inhibits metastasis. Immune profiling reveals enhanced infiltration of effector CD8⁺ and CD4⁺ T cells, reduced regulatory T cells, and decreased expression of exhaustion markers such as TIM-3 and PD-1. Macrophage populations are shifted from immunosuppressive M2 to proinflammatory M1 phenotypes, with increased monocyte infiltration, indicating robust myeloid reprogramming. Although mRNA-expressed IL-12 monotherapy exhibits potent antitumor effects, the combination of IL-15, IL-18, and Caspase-1 elicits superior therapeutic efficacy. Although high-dose treatment induces hepatotoxicity and weight loss, a reduced-dose regimen maintains efficacy with improved safety.
CONCLUSIONS: This study demonstrates the therapeutic potential of mRNA-based cytokine combinations to transform the ovarian cancer immune landscape. The modularity, localized delivery, and tunable expression of this platform provide a compelling framework for future mRNA immunotherapies targeting solid tumors with immunosuppressive TMEs.